Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None2022202120202019201820172016 November 3, 2022 Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results September 7, 2022 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference August 31, 2022 Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis August 4, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results June 25, 2022 Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ June 6, 2022 Madrigal Pharmaceuticals Supports International NASH Day on June 9 June 2, 2022 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences May 17, 2022 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences May 9, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results April 28, 2022 Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9 Pagination Current page 1 Page 2 Next page
Madrigal press releases are available below. Search them by keyword or browse by date. Year None2022202120202019201820172016 November 3, 2022 Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results September 7, 2022 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference August 31, 2022 Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis August 4, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results June 25, 2022 Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ June 6, 2022 Madrigal Pharmaceuticals Supports International NASH Day on June 9 June 2, 2022 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences May 17, 2022 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences May 9, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results April 28, 2022 Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9 Pagination Current page 1 Page 2 Next page
November 3, 2022 Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
September 7, 2022 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022 Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
August 4, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
June 25, 2022 Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
May 9, 2022 Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
April 28, 2022 Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
